LeMaitre Vascular Inc. (LMAT)
LeMaitre Vascular Inc. (LMAT) Stock Price, Analysis & Data
| Bid | 88.97 |
| Market Cap | 1.88B |
| Revenue (ttm) | 262.43M |
| Net Income (ttm) | 65.67M |
| Beta | 0.52 |
| EPS (ttm) | 2.86 |
| PE Ratio (ttm) | 28.72 |
| Forward PE | 25.66 |
| P/B (ttm) | 4.47 |
| P/S (ttm) | 7.16 |
| Earnings Date | Nov 5, 2026 |
| Ask | 109.9 |
| Volume | 317,936 |
| Avg. Volume (20D) | 359,700 |
| Open | 81.96 |
| Previous Close | 82.84 |
| Day's Range | 79.97 - 82.19 |
| 52-Week Range | 78.65 - 118.01 |
| Analyst | Buy |
| Price Target | 102 (24.19%) |
| Dividends | $1 (1.22%) |
| Ex-Dividend Date | Aug 20, 2026 |
About LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi i...
Financial Performance
In 2025, LeMaitre Vascular's revenue was 249.6M, an increase of 13.53% compared to the previous year's 219.86M. Earnings were 57.73M, an increase of 31.1%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for LMAT stock is "Buy". The 12-month stock price forecast is 102, which is upside of 24.19% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
